Texas HB3086 mandates pharmaceutical drug manufacturers to report prescription drug costs and factors causing cost increases.

HB3086 requires pharmaceutical drug manufacturers to submit annual reports to the Texas Department of Health and Safety detailing the wholesale acquisition costs of FDA-approved drugs sold in the state. For drugs with significant cost increases, manufacturers must provide additional information, including factors causing the increase and research and development costs. The department must publish this information on its website within 60 days of receiving the report. The bill also mandates consistency between the report and other public disclosures by the manufacturer.

Texas HB3086 mandates pharmaceutical drug manufacturers to report prescription drug costs and factors causing cost increases.

HB3086 requires pharmaceutical drug manufacturers to submit annual reports to the Texas Department of Health and Safety detailing the wholesale acquisition costs of FDA-approved drugs sold in the state. For drugs with significant cost increases, manufacturers must provide additional information, including factors causing the increase and research and development costs. The department must publish this information on its website within 60 days of receiving the report. The bill also mandates consistency between the report and other public disclosures by the manufacturer.